Patents by Inventor John Sedy

John Sedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTLA Fusion Protein Agonists and Uses Thereof
    Publication number: 20240247047
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: February 15, 2024
    Publication date: July 25, 2024
    Applicants: Sanford Burnham Prebys Medical Discovery Institute, PFIZER INC.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • BTLA fusion protein agonists and uses thereof
    Patent number: 11939367
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: March 26, 2024
    Assignees: Sanford Burnham Prebys Medical Discovery Institute, Pfizer Inc.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • MODULATION OF IMMUNE RESPONSE USING BTLA AGONIST ANTIBODIES
    Publication number: 20220380468
    Abstract: The present invention relates to the seminal discovery that BTLA agonist antibodies modulate the immune system. Specifically, the present invention provides antibodies which bind BTLA in the activated state enhancing BTLA signaling. The present invention further provides methods of treating immune and inflammatory diseases and disorders with a BTLA agonist antibody.
    Type: Application
    Filed: May 16, 2022
    Publication date: December 1, 2022
    Inventors: Carl F. WARE, John SEDY, Paula NORRIS
  • Compositions and methods for treating autoimmune and inflammatory disorders
    Patent number: 11365221
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: June 21, 2022
    Assignee: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Carl Ware, John Sedy
  • Modulation of immune response using BTLA agonist antibodies
    Patent number: 11352428
    Abstract: The present invention relates to the seminal discovery that BTLA agonist antibodies modulate the immune system. Specifically, the present invention provides antibodies which bind BTLA in the activated state enhancing BTLA signaling. The present invention further provides methods of treating immune and inflammatory diseases and disorders with a BTLA agonist antibody.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 7, 2022
    Assignee: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Carl F. Ware, John Sedy, Paula Norris
  • BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
    Publication number: 20220025017
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: March 1, 2021
    Publication date: January 27, 2022
    Inventors: Carl F. WARE, John SEDY, Tigran AIVAZIAN, Brian MILLER, Natasha K. CRELLIN
  • COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
    Publication number: 20210122788
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Application
    Filed: June 8, 2020
    Publication date: April 29, 2021
    Inventors: Carl WARE, John SEDY
  • BTLA fusion protein agonists and uses thereof
    Patent number: 10961297
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 30, 2021
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, PFIZER INC.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Compositions and methods for treating autoimmune and inflammatory disorders
    Patent number: 10717765
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: July 21, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Carl Ware, John Sedy
  • COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
    Publication number: 20190119329
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Application
    Filed: May 25, 2018
    Publication date: April 25, 2019
    Inventors: Carl Ware, John Sedy
  • BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
    Publication number: 20180170999
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: June 29, 2016
    Publication date: June 21, 2018
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • MODULATION OF IMMUNE RESPONSE USING BTLA AGONIST ANTIBODIES
    Publication number: 20180155426
    Abstract: The present invention relates to the seminal discovery that BTLA agonist antibodies modulate the immune system. Specifically, the present invention provides antibodies which bind BTLA in the activated state enhancing BTLA signaling. The present invention further provides methods of treating immune and inflammatory diseases and disorders with a BTLA agonist antibody.
    Type: Application
    Filed: April 29, 2016
    Publication date: June 7, 2018
    Inventors: Carl F. WARE, John SEDY, Paula NORRIS
  • Compositions and methods for treating autoimmune and inflammatory disorders
    Patent number: 9982023
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: May 29, 2018
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Carl F. Ware, John Sedy